Shots:

• Novartis signed an agreement with CEPI and Gavi- worth $750M to support the manufacturing- procurement and distribution of 300M doses of the vaccine- with delivery initiating by the end of the year. The company also collaborated with SII to supply 1B doses for low/middle-income countries- with a commitment to provide 400M before the end of 2020
• The agreement with CEPI and Gavi marks the first advanced market commitment through the Access to COVID-19 Tools (ACT) accelerator. The mechanism will work to ensure the fair allocation and distribution of the vaccine across the globe. CEPI will lead development and manufacturing while Gavi will lead the procurement within the global mechanism
• Additionally- AstraZeneca agreed to supply 400M doses to the US and UK after reaching a license agreement with Oxford University for AZD1222. The University has initiated P-II/III trial of AZD1222 in ~10-000 adult volunteers

Click here ­to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca